Yukio Nagasaki

ホーム > メンバー > Yukio Nagasaki

	Yukio Nagasaki was born in 1959. He received B.S. and Ph.D. degrees in Engineering School of Science University of Tokyo in 1982, and 1987. Since 1987, he was working at the Science University of Tokyo as a Research Associate, Assistant Professor, Associate Professor, and Professor. In 2004, he moved to the Graduate School of Pure and Applied Sciences, University of Tsukuba. He published more than 200 scientific papers. He received several awards such as The Award of the Japanese Society for Biomaterials (2014), The Nagai Award from The Japan Society of Drug Delivery System (2015), and the Polymer Society award, Japan (2017). He is now focusing on the development of "self-assembling drugs" supported by the MEXT budget (Grant #19H05458). We started a nano-particle type antioxidant, which presents mitochondrial dysfunction of normal cells and works effectively the oxidative stress-related diseases such as Alzheimer's disease and cancers. Based on this mechanism, he started to create a new concept of self-assembling drugs, which can improve their therapeutic effect and/or decrease their adverse effects, which cannot obtain by only simple compounds. Using this concept, we are now developing versatile drugs based on amino acids and short-chain fatty acids.

Yukio Nagasaki was born in 1959. He received B.S. and Ph.D. degrees in Engineering School of Science University of Tokyo in 1982, and 1987. Since 1987, he was working at the Science University of Tokyo as a Research Associate, Assistant Professor, Associate Professor, and Professor. In 2004, he moved to the Graduate School of Pure and Applied Sciences, University of Tsukuba. He published more than 200 scientific papers. He received several awards such as The Award of the Japanese Society for Biomaterials (2014), The Nagai Award from The Japan Society of Drug Delivery System (2015), and the Polymer Society award, Japan (2017). He is now focusing on the development of "self-assembling drugs" supported by the MEXT budget (Grant #19H05458). We started a nano-particle type antioxidant, which presents mitochondrial dysfunction of normal cells and works effectively the oxidative stress-related diseases such as Alzheimer's disease and cancers. Based on this mechanism, he started to create a new concept of self-assembling drugs, which can improve their therapeutic effect and/or decrease their adverse effects, which cannot obtain by only simple compounds. Using this concept, we are now developing versatile drugs based on amino acids and short-chain fatty acids.